Reduced-dose Alemtuzumab for Kidney Transplant Rejection

Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients

NCT00183248 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

mTor-inhibitor (EVERolimus) Based Immunosuppressive Strategies for CNI Minimisation in OLD for Old Renal Transplantation

NCT01028092 ·Status: COMPLETED ·Phase: PHASE3

Evaluation of Desensitization Protocols in HLA-incompatible Kidney-transplant Candidates

NCT03507348 ·Status: TERMINATED ·Phase: NA

Efficacy and Safety of AEB071 Versus Tacrolimus in Combination With Mycophenolate Acid Sodium, Basiliximab and Steroids in Preventing Acute Rejection After Kidney Transplantation

NCT00492869 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Thiazide Diuretics for Hypertension in Kidney Transplant Recipients Using Tacrolimus

NCT02644395 ·Status: COMPLETED ·Phase: PHASE3

Mycophenolate-Based Therapy for Kidney Transplant Recipients Without HLA-DQ Mismatch

NCT06493526 ·Status: RECRUITING ·Phase: PHASE4

Efficacy and Safety in Imlifidase Desensitized Kidney Tx Patients, Including Two Non-Comparative Reference Cohorts

NCT05369975 ·Status: COMPLETED ·Phase: PHASE3

Pilot Study to Investigate a Steroid Free Immunosuppressive Regimen for Renal Transplant Recipients

NCT00306397 ·Status: COMPLETED ·Phase: PHASE4

Bortezomib in Rejection of Kidney Transplants

NCT02201576 ·Status: COMPLETED ·Phase: PHASE2

Impact of Proteasome Inhibition on Anti-Donor HLA Antibody Production After Kidney Transplantation

NCT01349595 ·Status: TERMINATED ·Phase: PHASE2

Standard Versus Prolonged-release Tacrolimus Monotherapy After Alemtuzumab Induction in Kidney Transplantation

NCT00807144 ·Status: COMPLETED ·Phase: PHASE4

Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney Transplantation

NCT02711202 ·Status: COMPLETED ·Phase: NA

Everolimus Versus Mycophenolate Mofetil in Combination With Reduced Dose Cyclosporine Microemulsion in Maintenance Heart Transplant Recipients

NCT00170859 ·Status: COMPLETED ·Phase: PHASE4

Reducing the Risk of Transplant Rejection: Simultaneous Kidney and Bone Marrow Transplant

NCT00063817 ·Status: COMPLETED ·Phase: PHASE1

Th1, Th2 and Monokine Responses as Risk Factors of Renal Transplant Rejection

NCT00150891 ·Status: COMPLETED

Study to Evaluate the Efficacy, Safety and Tolerability of Everolimus in de Novo Renal Transplant Recipients Participating in the Eurotransplant Senior Program

NCT00956293 ·Status: TERMINATED ·Phase: PHASE4

Desensitization in Kidney Transplantation

NCT00908583 ·Status: COMPLETED ·Phase: PHASE4

Renal Transplantation in the Elderly - nEverOld Study

NCT01631058 ·Status: UNKNOWN ·Phase: PHASE4

Efficacy and Safety of a Reduced Immunosuppression vs. Standard Triple Therapy in Senior Renal Transplant Recipients

NCT02453867 ·Status: UNKNOWN ·Phase: PHASE4

Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies

NCT00307125 ·Status: COMPLETED ·Phase: PHASE2

Comparison of Immunosuppression on Progression of Arteriosclerosis in Renal Transplantation

NCT01276834 ·Status: TERMINATED ·Phase: PHASE4

Reasons for Mycophenolate Mofetil Dose Reduction and Impact on Graft Outcome in Renal Transplant Recipients

NCT01496703 ·Status: COMPLETED

De Novo Everolimus-based Therapy for Renal Transplantation Using Rituximab Induction

NCT01312064 ·Status: TERMINATED ·Phase: PHASE4

A Pilot Study Comparing the Use of Low-target Versus Conventional Target Advagraf

NCT01265537 ·Status: COMPLETED ·Phase: NA

Comparison of CNI-based Regimen Versus CNI-free Regimen in Kidney Transplant Recipients.

NCT00332839 ·Status: TERMINATED ·Phase: PHASE4